AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca chief Pascal Soriot eyes record £28m pay bonanza
Pascal Soriot is already the highest-paid FTSE 100 chief executive, landing £17.7m last year at the Anglo-Swedish drugs giant.
www.thisismoney.co.uk
November 1, 2026 at 3:52 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports reut.rs/4zshz0f
AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports
AstraZeneca made an about $10 billion offer to acquire obesity drugmaker Rhythm Pharmaceuticals , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
reut.rs
November 4, 2026 at 9:15 PM
AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports reut.rs/4zshz0f
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
November 2, 2026 at 2:54 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Rhythm specializes in treatments for metabolic conditions and severe obesity. on.wsj.com/47YAEv0
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
Rhythm specializes in treatments for metabolic conditions and severe obesity.
on.wsj.com
November 4, 2026 at 9:00 PM
Rhythm specializes in treatments for metabolic conditions and severe obesity. on.wsj.com/47YAEv0
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
The three-year restructuring programme will redirect savings into a pipeline of more than 180 projects as the drugmaker seeks to reach $80bn in annual revenue by 2030.
www.easterneye.biz
October 31, 2026 at 11:13 AM
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a programme to save $1.5 billion (€1.34bn) a year to invest back into developing new medicines.
l.euronews.com
October 30, 2026 at 9:17 PM
AstraZeneca profit jumps 23% as it unveils major savings plan
ASTRAZENECA MADE $10 BILLION OFFER FOR RHYTHM PHARMACEUTICALS – WSJ
November 4, 2026 at 9:14 PM
ASTRAZENECA MADE $10 BILLION OFFER FOR RHYTHM PHARMACEUTICALS – WSJ
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Board approves conveyance of 82.028 acres in Rivanna Futures to EDA to enable AstraZeneca project
Albemarle County approved a resolution to convey approximately 82.028 acres (Land Bay 82) to the county Economic Development Authority, enabling the EDA to provide incentives and convey property to AstraZeneca, a project staff said entails a $4.5 billion investment and about 600 jobs.
citizenportal.ai
November 2, 2026 at 8:07 AM
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
ASTRAZENECA OFFERED TO BUY RHYTHM PHARMA AT $124/SHR CASH: WSJ
November 4, 2026 at 9:04 PM
ASTRAZENECA OFFERED TO BUY RHYTHM PHARMA AT $124/SHR CASH: WSJ
#$AZN AstraZeneca combines a strong oncology franchise, rising profitability, and a promising clinical pipeline, but patent expirations and demanding expectations for future cash generation limit its current margin of safety.
intickers.com/reports/azn/
intickers.com/reports/azn/
AstraZeneca PLC (AZN) Stock Analysis | InTickers
AstraZeneca combines a strong oncology franchise, rising profitability, and a promising clinical pipeline, but…
intickers.com
November 5, 2026 at 12:25 AM
#$AZN AstraZeneca combines a strong oncology franchise, rising profitability, and a promising clinical pipeline, but patent expirations and demanding expectations for future cash generation limit its current margin of safety.
intickers.com/reports/azn/
intickers.com/reports/azn/
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, according to three people
www.centraloregondaily.com
November 4, 2026 at 10:53 PM
AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
RESTATING POST : ASTRAZENECA MADE $10 BILLION OFFER FOR RHYTHM PHARMACEUTICALS- WSJ
X
X
November 4, 2026 at 9:00 PM
RESTATING POST : ASTRAZENECA MADE $10 BILLION OFFER FOR RHYTHM PHARMACEUTICALS- WSJ
X
X
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
https://www.wsj.com/health/pharma/as...
https://www.wsj.com/health/pharma/as...
November 4, 2026 at 9:00 PM
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
https://www.wsj.com/health/pharma/as...
https://www.wsj.com/health/pharma/as...
Cambridge South - quietly brilliant railway architecture
November 4, 2026 at 9:57 AM
Cambridge South - quietly brilliant railway architecture
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
A AstraZeneca reportou um aumento na receita e no lucro no terceiro trimestre, uma vez que as vendas expressivas de medicamentos oncológicos c...
valor.globo.com
October 30, 2026 at 1:09 PM
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
AstraZeneca, United Kingdom is hiring:
Senior Scientist in Data Science
#medicine #datascienceinoncology
Senior Scientist in Data Science
#medicine #datascienceinoncology
November 3, 2026 at 2:29 AM
AstraZeneca, United Kingdom is hiring:
Senior Scientist in Data Science
#medicine #datascienceinoncology
Senior Scientist in Data Science
#medicine #datascienceinoncology
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
AstraZeneca follows GSK with $1.5B annual savings push
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, including EMERALD-2.
endpoints.news
October 30, 2026 at 12:16 PM
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
November 2, 2026 at 9:38 AM
November 2, 2026 at 9:28 AM
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in oncology, cell therapy & AI.
endpoints.news
October 30, 2026 at 6:18 PM
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.